Table 2 Heart rate analyses

 Pre-existent bradycardia (heart rate < 60 min^− 1) during study treatment, n (%)

3 (13)

3 (13)

 Heart rate, mean (SD), beats per minute

65.2 (9.1)

61.6 (13.2)

 Duration of heart rate decrease > 20% from baseline, median (IQR), minutes

35.0 [2.5–77.5]

70.0 [7.5–157.5]

 Proportion of the study treatment duration represented by the duration of a heart rate decrease > 20% from baseline, median (IQR), %

14.6 [0.9–46.0]

69.4 [5.7–88.9]

 Duration of a heart rate increase > 20% from baseline, median (IQR), minutes

0 [0–7.5]

0 [0–12.5]

 Proportion of the study treatment duration represented by the duration of a heart rate increase > 20% from baseline, median (IQR), %

0 [0–4.9]

0 [0–7.4]

 Duration of bradycardia (heart rate < 60 min⁻¹), median (IQR), minutes

60.0 [10.0–145.0]

100.0 [47.5–155.0]

 Proportion of the study treatment duration represented by the duration of bradycardia (heart rate < 60 min⁻¹), median (IQR), %

32.1 [6.5–79.3]

82.1 [35.4–94.9]

 Pre-existent tachycardia (heart rate > 100 min^− 1), n (%)

2 (9)

1 (4)

 Duration of tachycardia (heart rate > 100 min⁻¹) during study treatment, median (IQR), minutes

0 [0–0]

0 [0–0]

 Proportion of the study treatment duration represented by the tachycardia (heart rate > 100 min^− 1) duration, median (IQR), %

0 [0–0]

0 [0–0]